The successful development of several coronavirus disease 2019 (COVID-19) vaccines has
substantially reduced morbidity and mortality in regions of the world where the vaccines …

Abstract COVID‐19 convalescent plasma (CCP) was among the few frontline therapies used
to treat COVID‐19. After large randomized controlled trials (RCTs) relying on late use in …

This contribution explores in a new statistical perspective the antibody responses to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus disease 2019 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than
231 million people globally, with more than 4.7 million deaths recorded by the World Health …

The successful development of several COVID-19 vaccines has substantially reduced
morbidity and mortality in regions of the world where the vaccines have been deployed …

Severe acute respiratory syndrome (SARS)-coronavirus (CoV), Middle Eastern respiratory
syndrome (MERS)-CoV, and SARS-CoV-2 have seriously threatened human life in the 21st …

Background Understanding the determinants of long-term immune responses to SARS-CoV-
2 and the concurrent impact of vaccination and emerging variants of concern will guide …

The rapidity of SARS-CoV-2 vaccination around the world has substantially reduced the
number of new cases of COVID-19 and their severity in highly vaccinated countries. The …

Background As at end of July 2021, the COVID-19 pandemic has been less severe in sub-
Saharan Africa than elsewhere. In Malawi, there have been two subsequent epidemic …

SARS-CoV-2 variants raise concern because of their high transmissibility and their ability to
evade neutralizing antibodies elicited by prior infection or by vaccination. Here we …